STOCKHOLM —Eliminating anthracyclines from the treatment regimen of children and adolescents newly diagnosed with acute promyelocytic leukemia (APL) is feasible and yields excellent positive outcomes in standard-risk and high-risk patients, new data suggest. At the 2026 European Hematology Association Congress, Franco Locatelli presented the final results of the ICC-APL-02 trial…
Read More
Chemo-Free Therapy in Pediatric Acute Promyelocytic Leukemia
